CJC-1295 (No DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH), modified to resist enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). Without the Drug Affinity Complex (DAC), it is commonly studied for its shorter half-life kinetics and pulsatile GH release characteristics in research models.
- Commonly studied for its binding to pituitary GHRH receptors and stimulation of endogenous GH secretion patterns
- Associated with research into the GH/IGF-1 axis, somatotroph cell signaling, and pituitary feedback regulation
- May support research into protein synthesis, nitrogen balance, and anabolic signaling cascades at the cellular level
- Observed in studies examining lipolysis, fat oxidation pathways, and adipose tissue metabolism
- Frequently paired with Ipamorelin in research protocols to study synergistic effects on GH pulse amplitude
For Research Use Only. This compound is intended exclusively for in-vitro laboratory research by qualified investigators. It is not intended for human or animal consumption, is not a pharmaceutical product, and has not been evaluated by the FDA for safety or efficacy.
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

